# US 2011/0212123 A1 · Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0212123 A1
- Document ID: US20110212123A1
- Status: Published application
- Kind: A1
- Application number: 13/032,543
- Filed: 2011-02-22
- Published: 2011-09-01
- Earliest claimed: 2006-01-13
- Assignees: Yisheng Biopharma (Singapore) Pte Ltd
- Inventors: Haixiang Lin; Lie Tao Victor Li
- Web page: https://patentgrep.com/patent/US20110212123A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

An immunogenic composition suitable for human use, the immunogenic composition comprising: (a) a polynucleotide adjuvant comprising: a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic, and at least one positive ion, wherein the immunogenic composition comprises polynucleotide adjuvant composition molecules with an average molecular size of greater than 9.0 Svedbergs; and (b) at least one antigen.

### Claim 25 (depends on 24)

The immunogenic composition according to claim 24, wherein the immunogenic composition comprises polynucleotide adjuvant composition molecules have an average molecular size of greater than 12.0 Svedbergs.

### Claim 26 (depends on 24)

The immunogenic composition according to claim 24, wherein the antibiotic is kanamycin and the positive ion is calcium.

### Claim 27 (depends on 24)

The immunogenic composition according to claim 24, wherein the antigen is an inactivated microorganism, attenuated microorganism, recombinant polypeptide, synthetic polypeptide, attenuated toxin, protein subunit, polysaccharide conjugate, tumor antigen, or recombinant DNA.

### Claim 28 (depends on 24)

The immunogenic composition according to claim 24, wherein the antigen is a viral antigen.

### Claim 29 (depends on 28)

The immunogenic composition according to claim 28, wherein the viral antigen is an antigen of adeniviridae, arenaviridae, astroviridae, bunyaviridae, caliciviridae, coronaviridae, flaviviridae, hepadnaviridae, hepatitis delta virus, hepeviridae, herpesviridae, mononegavirales, nidovirales, picornaviridae, orthomyxoviridae, papillomaviridae, paramyxoviridae, parvoviridae, polyomaviridae, poxyiridae, rhabdoviridae, reoviridae, retroviridae or togaviridae.

### Claim 30 (depends on 24)

The immunogenic composition according to claim 24, wherein the antigen is a bacterial antigen.

### Claim 31 (depends on 30)

The immunogenic composition according to claim 30, wherein the bacterial antigen is an antigen of actinobacteria, chlamydia, firmicutes, proteobacteria, or spirochetes.

### Claim 32 (depends on 24)

The immunogenic composition according to claim 24, wherein the antigen is a fungal antigen.

### Claim 33 (depends on 32)

The immunogenic composition according to claim 32, wherein the fungal antigen is an antigen of ascomycota or basidiomycota.

### Claim 34 (depends on 24)

The immunogenic composition according to claim 24, wherein the antigen is a parasitic antigen.

### Claim 35 (depends on 34)

The immunogenic composition according to claim 34, wherein the parasitic antigen is an antigen of phylum sarcomastigophora, phuylum apiicomplexa, phylum ciliophora, phylum plathyhelminthes, phylum nematoda or phylum arthropoda.

### Claim 36 (depends on 24)

The immunogenic composition according to claim 24, wherein the antigen is a cancer antigen.

### Claim 37 (depends on 36)

The immunogenic composition according to claim 36, wherein the cancer antigen is an antigen of bone, brain, breast, digestive/gastrointestinal, endocrine, eye, genitourinary, germ cell, gynecologic, head and neck, hematological/blood, lung, musculoskeletal, neurologic, respiratory/thoracic or skin cancer.

### Claim 38 (depends on 24)

The immunogenic composition according to claim 24, wherein the composition comprises two or more antigens.

### Claim 39 (depends on 24)

The immunogenic composition according to claim 24, further comprising at least one immunomodulator.

### Claim 40 (depends on 24)

A kit comprising the immunogenic composition of claim 24.

### Claim 41 (depends on 24)

A method for eliciting an immune response to an antigen, the method comprising:
administering to the host the immunogenic composition of claim 24.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the host has an infectious disease and said antigen is from the pathogen causing the infectious disease.

### Claim 43 (depends on 41)

The method according to claim 41, wherein said administering comprises parenteral injection, intramuscular injection, intraperitoneal injection, intravenous injection, subcutaneous injection, intranasal delivery, topical delivery, transdermal delivery or intradermal delivery.
